These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

594 related items for PubMed ID: 11092994

  • 1. Effects of angiotensin-converting enzyme inhibitor, angiotensin II receptor antagonist and calcium antagonist on urinary podocytes in patients with IgA nephropathy.
    Nakamura T, Ushiyama C, Suzuki S, Hara M, Shimada N, Sekizuka K, Ebihara I, Koide H.
    Am J Nephrol; 2000; 20(5):373-9. PubMed ID: 11092994
    [Abstract] [Full Text] [Related]

  • 2. [Additive antiproteinuric effect of angiotensin II receptor antagonist and angiotensin-converting enzyme inhibitor in patients with chronic glomerulonephritis].
    Iimura O, Kusano E, Tanba K, Yanagiba S, Amemiya M, Ando Y, Honma S, Muto S, Asano Y.
    Nihon Jinzo Gakkai Shi; 2003 Jul; 45(5):439-44. PubMed ID: 14509219
    [Abstract] [Full Text] [Related]

  • 3. The effects of dual blockade of the renin-angiotensin system on urinary protein and transforming growth factor-beta excretion in 2 groups of patients with IgA and diabetic nephropathy.
    Song JH, Lee SW, Suh JH, Kim ES, Hong SB, Kim KA, Kim MJ.
    Clin Nephrol; 2003 Nov; 60(5):318-26. PubMed ID: 14640237
    [Abstract] [Full Text] [Related]

  • 4. Comparison between the angiotensin II receptor antagonist candesartan cilexetil and the angiotensin-converting enzyme inhibitor trandolapril in microalbuminuria of patients with early diabetic nephropathy.
    Nakamura T, Ushiyama C, Suzuki S, Shimada N, Sekizuka K, Ebihara I, Takahashi Y, Tanaka A, Koide H.
    Nephron; 2000 Oct; 86(2):247. PubMed ID: 11015024
    [No Abstract] [Full Text] [Related]

  • 5. Antiproteinuric efficacy of verapamil in comparison to trandolapril in non-diabetic renal disease.
    Hemmelder MH, de Zeeuw D, de Jong PE.
    Nephrol Dial Transplant; 1999 Jan; 14(1):98-104. PubMed ID: 10052485
    [Abstract] [Full Text] [Related]

  • 6. [Change from ACE inhibitor, Ca-antagonist or beta-blocker to candesartan cilexetil: better efficacy and tolerance. SWITCH study (German study segment)].
    Baumgart P, Reismann J, Pohlmeyer H, Düsing R.
    Dtsch Med Wochenschr; 2001 May 11; 126(19):547-50. PubMed ID: 11402910
    [Abstract] [Full Text] [Related]

  • 7. Beneficial action of candesartan cilexetil plus amlodipine or ACE inhibitors in chronic nondiabetic renal disease.
    Homma K, Hayashi K, Kanda T, Yoshioka K, Takamatsu I, Tatematsu S, Kumagai H, Wakino S, Saruta T.
    J Hum Hypertens; 2004 Dec 11; 18(12):879-84. PubMed ID: 15295613
    [Abstract] [Full Text] [Related]

  • 8. Additive antiproteinuric effect of combination therapy with ACE inhibitor and angiotensin II receptor antagonist: differential short-term response between IgA nephropathy and diabetic nephropathy.
    Kim MJ, Song JH, Suh JH, Lee SW, Kim GA.
    Yonsei Med J; 2003 Jun 30; 44(3):463-72. PubMed ID: 12833584
    [Abstract] [Full Text] [Related]

  • 9. Use of candesartan cilexetil decreases proteinuria in renal transplant patients with chronic allograft dysfunction.
    Omoto K, Tanabe K, Tokumoto T, Shimmura H, Ishida H, Toma H.
    Transplantation; 2003 Oct 27; 76(8):1170-4. PubMed ID: 14578748
    [Abstract] [Full Text] [Related]

  • 10. Effect of candesartan cilexetil (TCV-116) in rats with chronic renal failure.
    Noda M, Matsuo T, Fukuda R, Ohta M, Nagano H, Shibouta Y, Naka T, Nishikawa K, Imura Y.
    Kidney Int; 1999 Sep 27; 56(3):898-909. PubMed ID: 10469358
    [Abstract] [Full Text] [Related]

  • 11. Verapamil versus amlodipine in proteinuric non-diabetic nephropathies treated with trandolapril (VVANNTT study): design of a prospective randomized multicenter trial.
    Boero R, Rollino C, Massara C, Vagelli G, Gonella M, Berto IM, Bajardi P, Perosa P, Malcangi U, Giorgi MP, Ghezzi PM, Borzumati M, Baroni AM, Cogno C, Triolo G, Angelini D, Antonelli A, Quarello F.
    J Nephrol; 2001 Sep 27; 14(1):15-8. PubMed ID: 11281338
    [Abstract] [Full Text] [Related]

  • 12. Combination therapy of trandolapril and candesartan cilexetil reduces microalbuminuria and urinary endothelin-1 excretion in patients with type 2 diabetes.
    Nakamura T, Ushiyama C, Osada S, Takahashi Y, Shimada N, Ebihara I, Koide H.
    Clin Exp Nephrol; 2002 Sep 27; 6(3):135-9. PubMed ID: 24989952
    [Abstract] [Full Text] [Related]

  • 13. Antiproteinuric effect of candesartan cilexetil in Japanese subjects with type 2 diabetes and nephropathy.
    Haneda M, Kikkawa R, Sakai H, Kawamori R, Candesartan in Diabetic Nephropathy Study Group.
    Diabetes Res Clin Pract; 2004 Oct 27; 66(1):87-95. PubMed ID: 15364166
    [Abstract] [Full Text] [Related]

  • 14. Antiproteinuric effect of candesartan cilexetil in patients with chronic glomerulonephritis.
    Kurokawa K, Abe K, Saruta T, Arakawa M, Kikkawa R, Ueda N, Onoyama K, Tomita K, Ogawa N.
    J Renin Angiotensin Aldosterone Syst; 2002 Sep 27; 3(3):167-75. PubMed ID: 12563567
    [Abstract] [Full Text] [Related]

  • 15. The effect of trandolapril and its fixed-dose combination with verapamil on proteinuria in normotensive adults with type 2 diabetes.
    Rubio-Guerra AF, Arceo-Navarro A, Vargas-Ayala G, Rodriguez-Lopez L, Lozano-Nuevo JJ, Gomez-Harper CT.
    Diabetes Care; 2004 Jul 27; 27(7):1688-91. PubMed ID: 15220247
    [Abstract] [Full Text] [Related]

  • 16. Effects of candesartan cilexetil on oxidative state and renal function in 5/6 nephrectomized rats.
    Sugimoto K, Tsuruoka S, Matsushita K, Fujimura A.
    J Hum Hypertens; 1999 Jan 27; 13 Suppl 1():S63-70; discussion S81. PubMed ID: 10076923
    [Abstract] [Full Text] [Related]

  • 17. Blocking angiotensin II ameliorates proteinuria and glomerular lesions in progressive mesangioproliferative glomerulonephritis.
    Nakamura T, Obata J, Kimura H, Ohno S, Yoshida Y, Kawachi H, Shimizu F.
    Kidney Int; 1999 Mar 27; 55(3):877-89. PubMed ID: 10027924
    [Abstract] [Full Text] [Related]

  • 18. Dual blockade of the rennin-angiotensin system versus maximal recommended dose of angiotensin II receptor blockade in chronic glomerulonephritis.
    Mori-Takeyama U, Minatoguchi S, Murata I, Fujiwara H, Ozaki Y, Ohno M, Oda H, Ohashi H.
    Clin Exp Nephrol; 2008 Feb 27; 12(1):33-40. PubMed ID: 18175062
    [Abstract] [Full Text] [Related]

  • 19. Effect of strict blood pressure control on proteinuria in renal patients treated with different antihypertensive drugs.
    García de Vinuesa S, Luño J, Gómez-Campderá F, Ridao N, Sánchez M, Dall'Anese C, Valderrábano F.
    Nephrol Dial Transplant; 2001 Feb 27; 16 Suppl 1():78-81. PubMed ID: 11369828
    [Abstract] [Full Text] [Related]

  • 20. Involvement of angiotensin II in progression of renal injury in rats with genetic non-insulin-dependent diabetes mellitus (Wistar fatty rats).
    Noda M, Matsuo T, Nagano-Tsuge H, Ohta M, Sekiguchi M, Shibouta Y, Naka T, Imura Y.
    Jpn J Pharmacol; 2001 Apr 27; 85(4):416-22. PubMed ID: 11388646
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 30.